… ProQR Receives Rare Pediatric Disease Designation from FDA … & CAMBRIDGE, Mass., Jan. 30, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to … said Daniel A. de Boer, chief executive officer of ProQR. “Both sepofarsen for LCA10, the most common cause of …
… ProQR Announces Presentations on Programs in Ophthalmology at … LEIDEN, the Netherlands, July 12, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to … II Presentation at OIS Retina Daniel de Boer, CEO of ProQR, will give a presentation highlighting the company’s …
… ProQR Achieves Successful Defense of New Challenge to its … (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through … the European Patent Office (EPO) by a strawman against ProQR’s granted patent EP 3 507 366 B1 , which relates to …
… ProQR Announces Annual Meeting of Shareholders to be Held May … (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through … be made available in the “Investors & Media” section of ProQR’s website ( www.proqr.com ) under “Financials and …
… ProQR Announces Fourth Quarter and Full Year 2021 Operating … & CAMBRIDGE, Mass., Feb. 24, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a … in Q2,” said Daniel A. de Boer, Founder and CEO of ProQR. “Based on the previous data we have reported, we …
… ProQR Announces $30 Million Strategic Convertible Debt Financing Agreement with Pontifax Ventures Extends ProQR’s cash runway into 2023 ProQR can trigger conversion of … retinal diseases,” said Momi Karako, partner at Pontifax. “ProQR has expertise in antisense oligonucleotides, a …
Phase 2/3 pivotal Illuminate trial of sepofarsen for LCA10 enrollment complete with top-line data anticipated in H1 2022; Brighten pediatric trial of sepofarsen to begin in 2021; additional data from Phase 1/2 InSight extension study to be reported in
First-in-human trial of AX-0810 will evaluate safety, tolerability, pharmacokinetics, and target engagement in healthy volunteers with initial data expected in Q4 2025Marks the first submitted Clinical Trial Application (CTA) advancing ProQR’s Axiomer™ ADAR-mediated RNA